| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3244ba8390b1f290f4ba36389c82488b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-036 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 |
| filingDate |
2004-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98c92073001620c3a28484d69916e7cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4925a6a5712add133be838b7be25f43c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1cf4a49f6e34bdefaa74558794a834a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_204bd25fa328a0993ce463bda74b7e8b |
| publicationDate |
2004-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2004339234-A |
| titleOfInvention |
Erythropoietin with high specific activity |
| abstract |
PROBLEM TO BE SOLVED: To provide an EPO having a novel glycosylation. SOLUTION: It consists essentially of glycosylated EPO molecules containing 4.3 or more N-acetyllactosamine units with respect to N-linked carbohydrate chains, or 13.0 or more N-acetyllactosamine units with respect to total N-glycosylation. (I) The proportion of carbohydrate chains that are expression products of foreign DNA in CHO cells and are composed of glycosylated EPO molecules derived from CHO cells and have N-acetyllactosamine repeats with respect to the total number of N-linked carbohydrate chains Is not less than 30%, or (ii) the EPO molecule is the expression product of endogenous DNA in human cells, and the proportion of carbohydrate chains having N-acetyllactosamine repeats with respect to the total number of carbohydrate chains is at least 10% An EPO composition, characterized in that: [Selection diagram] None |
| priorityDate |
1997-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |